Pexelizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Pexelizumab
Monoclonal antibody
TypeSingle-chain variable fragment
SourceHumanized (from mouse)
TargetComplement component 5
Clinical data
ATC code
  • none
Legal status
Legal status
  • investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
 ☒N☑Y (what is this?)  (verify)

Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting[1] and angioplasty,[2][3] among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.[4]

Current status[edit]

Alexion, the developer of pexelizumab, stopped development when the phase 3 trial indicated the heart-attack drug is no better than placebo.[5]

References[edit]

  1. ^ Clinical trial number NCT00088179 for "Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass" at ClinicalTrials.gov
  2. ^ Clinical trial number NCT00091637 for "Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction" at ClinicalTrials.gov
  3. ^ Testa L, Van Gaal WJ, Bhindi R, Biondi-Zoccai GG, Abbate A, Agostoni P, et al. (October 2008). "Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients". The Journal of Thoracic and Cardiovascular Surgery. 136 (4): 884–93. doi:10.1016/j.jtcvs.2007.12.062. PMID 18954626.
  4. ^ Mathew JP, Shernan SK, White WD, Fitch JC, Chen JC, Bell L, Newman MF (October 2004). "Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery". Stroke. 35 (10): 2335–9. doi:10.1161/01.STR.0000141938.00524.83. PMID 15331798.
  5. ^ Mitchell S (2 January 2007). "Analysis: Alexion's pexelizumab fails". United Press International.